Skip to main content
Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: Novel venom-based peptides (P13 and its derivative—M6) to maintain self-renewal of human embryonic stem cells by activating FGF and TGFβ signaling pathways

Fig. 1

The survival ability and expression levels of p-Erk1/2 and p-Smad2 in human ES cells. a The survival ability of the human ES cells treated with venom peptide P13; the concentration of P13 was 200 μM/L; 1 × PBS was the solvent of the same volume used to dissolve the peptides. The statistical significances are marked by asterisks—*p < 0.05, **p < 0.01, and ***p < 0.001—between the two indicated groups. b The survival ability of the human ES cells treated with P13 and its mutants (M5, M6, M10, and M11); the concentration of P13 and its mutants was 200 μM/L. c The expression of the total/phosphorylation Erk1/2 in different culture conditions (E6, E6 + TGFβ1, and E8) when treated with P13 (left). d The expression of total/phosphorylation Smad2 in different culture conditions (E6, E6 + FGF2, and E8) when treated with P13 (right); the concentration of FGF2 was 100 μg/L, and the concentration of TGFβ1 was 2 μg/L.

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512